1 Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin.Endocrinol.(Oxf) 1977;7:481-93.
2 Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin.Endocrinol.(Oxf) 1991;34:77-83.
3. Wilson S, Parle JV, Roberts LM, Roalfe AK, Hobbs FDR, Clark P, Sheppard MC, Gammage MD, Pattison HM, Franklyn JA. Prevalence of subclinical thyroid dysfunction in the elderly in England – the Birmingham Elderly Thyroid Study (BETS): a community based cross-sectional survey. J Clin Endocrinol Metab 2006;91:4809-4816
4 Falkenberg M, Kagedal B, Norr A. Screening of an elderly female population for hypo- and hyperthyroidism by use of a thyroid hormone panel. Acta Med.Scand. 1983;214:361-5.
5. Pirich C, Mulner M, Sinzinger H. Prevalence and relevance of thyroid dysfunction in 1922 cholesterol screening participants. J Clin Epidemiol. 2000;53:623-9.
6. Helfand M, Redern CC. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann Intern Med. 1998 15;129:144-58.
7. Nordyke RA, Gilbert FI, Jr., Harada AS. Graves' disease. Influence of age on clinical findings. Arch.Intern.Med. 1988;148:626-31.
8. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N.Engl.J.Med. 1998;338:712-8.
9. Franklyn JA, Sheppard MC, Maisonneuve P. Mortality in subjects treated for hyperthyroidism – a prospective cohort study examining the influence of thyroid status.JAMA 205;294:71-80
10. Klein I,.Ojamaa K. Thyroid hormone and the cardiovascular system: from theory to practice. J.Clin.Endocrinol Metab 1994;78:1026-7.
11. Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy; a matched case-control study. J Am Coll Cardiol 2007; 49:71-81
12. Osman F, Gammage MD, Franklyn JA. Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid 2002;12:483-7.
13. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J.Med. 1982;72:903-6.
14. Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin.North Am 1990;19:35-63.
15. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J.Clin.Endocrinol.Metab 1996;81:4278-89.
16. Franklyn JA, Betteridge J, Holder R, Sheppard MC. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis. Thyroid 1995;5:359-63.
17. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N.Engl.J.Med. 1995;332:767-73.
18. Franklyn JA, Ramsden DB, Sheppard MC. The influence of age and sex on tests of thyroid function. Ann.Clin.Biochem. 1985;22 ( Pt 5):502-5.
19. Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. J.Clin.Endocrinol.Metab 1994;78 :1368-71.
20. Hamburger JI. Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J.Clin.Endocrinol Metab 1980; 50:1089-93.
21. Singer PA. Thyroiditis. Acute, subacute, and chronic. Med.Clin.North Am 1991;75:61-77.
22. Bartalena L, Bogazzi F, Martino E. Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge. Clin.Endocrinol (Oxf) 2002;56 :23-4.
23. Gammage MD,.Franklyn JA. Amiodarone and the thyroid. Q.J.Med. 1987;62:83-6.
24. Franklyn JA. The management of hyperthyroidism. N.Engl.J.Med. 1994;330:1731-8.
25. Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J.Clin.Endocrinol Metab 1993;76:1516-21.
26. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J.Clin.Endocrinol Metab 1990;70:675-9.
27. Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin.North Am 1998;27:225-47.
28. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA . Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J.Clin.Endocrinol.Metab 2000;85:1038-42.
29. Orsinelli DA. Current recommendations for the anticoagulation of patients with atrial fibrillation. Prog.Cardiovasc.Dis. 1996;39:1-20.
30. Bartalena L, Brogioni S, Grasso L, Velluzzi F, Martino E. Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. J.Endocrinol Invest 1994;17:269-74.
31. Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. Circulation 2002;105:1275-7.
32. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J.Clin.Endocrinol Metab 1996;81:2930-3.
33. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 1999;353:2111-5.
34. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N.Engl.J.Med. 1992;326:1733-8.
35. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N.Engl.J.Med. 1998;338:73-8.
36. Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin.Endocrinol.(Oxf) 1991;34:71-6.
37. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study . Thyroid 1997;7:247-51.
38. Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N.Engl.J.Med. 1984;311:426-32.
39. Franklyn JA, Daykin J, Holder R, Sheppard MC. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism. QJM. 1995;88:175-80.
40. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J.Clin.Endocrinol.Metab 2001;86:3611-7.
41. Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995;5:243-7.
42. Vanderpump MP, Ahlquist JA, Franklyn JA, Clayton RN. Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. BMJ 1996;313 :539-44.
43. Reid DJ. Hyperthyroidism and hypothyroidism complicating the treatment of thyrotoxicosis. Br.J.Surg. 1987;74:1060-2.
44. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann.Surg. 1998;228:320-30.
45. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000 Feb 28;160(4):526-34.
46. Parle JV, Franklyn JA, Cross KW, Jones SR , Sheppard MC. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br.J.Gen.Pract. 1993;43:107-9.
47. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N.Engl.J.Med. 1994;331:1249-52.
48. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006 1;295:1033-41.
49. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FDR, Wilson S, Sheppard MC, Franklyn JA. Association between serum free T4 concentration and atrial fibrillation. Arch Int Med 2007 (in press)
50. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001;358:861-5.
51. Faber J, Jensen IW, Petersen L, Nygaard B , Hegedus L, Siersbaek-Nielsen K . Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin.Endocrinol (Oxf) 1998; 48:285-90.
52. Bauer DC, Ettinger B, Nevitt MC, Stone KL; Study of Osteoporotic Fractures Research Group.Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001 3;134:561-8.
53. Sheppard MC, Holder R, Franklyn JA. Levothyroxine treatment and occurrence of fracture of the hip. Arch Int Med 2001;162:338-343.
54. Surks 54. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Evidence-based consensus guidelines for the diagnosis and management of subclinical thyroid disease .JAMA 2004;291:228-38